<PAGE> 1
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported)
April 20, 1998 (April 17, 1998)
Commission File No. 0-11772
-------
NU-TECH BIO-MED, INC.
---------------------
(Exact name of registrant as specified in its charter)
Delaware 25-1411971
-------- ----------
(State or other jurisdiction of (IRS Employer Identification No.)
incorporation of organization)
476 Main Street, Suite 3-DFL, Wakefield, Rhode Island 02879
- ----------------------------------------------------- -----
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: (401) 789-9995
--------------------------------------------
(Former name or former address, if changed since last report.)
Page 1 of 3
<PAGE> 2
ITEM 5. OTHER EVENTS
The Company has been advised, by letter dated April 17, 1998, from The
Nasdaq Stock Market, that Nasdaq has commenced proceedings to delist the
Company's Common Stock from inclusion in the SmallCap Market of The Nasdaq Stock
Market by reason of the inability of the Company to file its Annual Report on
Form 10-KSB for the year ended December 31, 1997. The Company has requested a
hearing with respect to the delisting proceedings. If the request for a hearing
is denied, the Common Stock will be delisted as of the opening of business on
April 24, 1998. Even if a hearing is granted, there is no assurance that the
Company will be able to maintain the listing of the Common Stock. Commencing
April 21, 1998, and pending a final decision concerning delisting, the Company's
symbol on Nasdaq will be "NTBME."
The inability of the Company to file its Annual Report on Form 10-KSB
was occasioned because the audit of the Company's financial statements for the
year ended December 31, 1997, has been delayed by reason of a pending change in
the Company's independent auditors.
Page 2 of 3
<PAGE> 3
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report on Form 8-K to be signed on its
behalf by the undersigned hereunto duly authorized.
NU-TECH BIO-MED, INC.
By: /s/ J. Marvin Feigenbaum
------------------------
J. Marvin Feigenbaum
Chairman of the Board,
President, Chief Executive
and Chief Financial Officer
Dated: April 20, 1998
Page 3 of 3
